When a new drug is ready for the market, failure is not an option. But risks such as increased regulations, market access barriers, and supply chain challenges can result in missed opportunities for patients as well as the pharmaceutical company.
IPM’s commercialization experts have assembled a guide to integrate project, program, and portfolio leadership into your drug launch program. Once you submit your information, you will receive access to the complete article, which includes an examination of the importance of and recommendations for managing these five key areas:
- Cross-functional interactions
- External stakeholders, focusing on patients, healthcare providers, and payers
- Strategic alliances and other partners
- Scope and schedule
- Risk and contingency plans
Due to the enduring impact the pandemic is having on commercialization, the piece also includes a look at how pharmaceutical companies are responding to limited access to internal teams, partners, and stakeholders.